-
Oct 14, 2024 | 
mibluedaily.com | Joshua J. Meeks
Each day, approximately in the United States turn 65, making them eligible for health insurance coverage through the federally managed Medicare program. Additionally, some individuals younger than 65 may be eligible for Medicare, including those with a long-term disability or certain diseases. There are many Medicare coverage options individuals should understand before picking the right plan for them. There are two main distinctions between Medicare plans: Original Medicare and Medicare Advantage.
-
Sep 30, 2024 | 02605-8/abstract?rss=yes&sz=64)
europeanurology.com | Roger Li |Joshua A. Linscott |James Catto |Joshua J. Meeks |Siamak Daneshmand |Bishoy M Faltas | +4 more
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes aDepartment of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USAbDepartment of Immunology, H.
-
Jul 2, 2024 | 
nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024In the version of the article initially published, in the key to Fig. 2b, the red diamond representing “Recurrence/NR” has been corrected to a green diamond to match the graph. This correction has been made to the HTML and PDF versions of the article. About this articleLi, R., Shah, P.H., Stewart, T.F. et al.
-
Jun 18, 2024 | 
nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat
Correction to: Nature Medicine https://doi.org/10.1038/s41591-024-03025-3, published online 6 June 2024In the version of the article initially published, the text “Immune-related adverse effects were exclusively associated with pembrolizumab” and, in the following sentence, also referring to adverse effects, “…all related to pembrolizumab” has been removed from the Abstract.
-
Jun 6, 2024 | 
nature.com | Roger Li |Joshua J. Meeks |Ashish M. Kamat
AbstractCretostimogene grenadenorepvec is a serotype-5 oncolytic adenovirus designed to selectively replicate in cancer cells with retinoblastoma pathway alterations, previously tested as monotherapy in bacillus Calmette–Guérin (BCG)-experienced non-muscle-invasive bladder cancer.
-
May 4, 2024 | 
onclive.com | Joshua J. Meeks
Joshua J. Meeks, MD, PhD, the Edward M. Schaeffer, MD, PhD, Professor of Urology and an associate professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, discusses key takeaways from a session that he participated in during the 2024 American Urological Association Annual Meeting regarding effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.
-
Feb 28, 2024 | 
urotoday.com | Joshua J. Meeks
Zach Klaassen and Joshua Meeks discuss the ongoing BCG shortage impacting bladder cancer treatment, tracing its origins back to production issues in 2012 and guideline changes in 2016 that increased BCG demand. They highlight the shift towards using Gemcitabine-Docetaxel (Gem/Doce) as both a salvage and primary treatment for high-risk bladder cancer due to its effectiveness and availability.
-
Feb 2, 2024 | 
cancernetwork.com | Joshua J. Meeks
Collaborating with other providers and limiting dosing for certain patients with bladder cancer are some strategies that may help with navigating the current shortage of Bacillus Calmette-Guerin (BCG), said Joshua J. Meeks, MD, PhD, BS.
-
Aug 10, 2023 | 
jamanetwork.com | Andrea Necchi |Vita-Salute San Raffaele |Susan F. Slovin |Joshua J. Meeks
Immunotherapy in the Treatment of Localized Genitourinary Cancers
Abstract
Importance
A true revolution in the management of advanced genitourinary cancers has occurred with the discovery and adoption of immunotherapy (IO). The therapeutic benefits of IO were recently observed not to be solely confined to patients with disseminated disease but also in select patients with localized and locally advanced genitourinary neoplasms.
-
Jul 25, 2023 | 
urotoday.com | Joshua J. Meeks
Read the Full Video TranscriptAshish Kamat: Hello and welcome to UroToday's Bladder Cancer Center of Excellence. I'm Ashish Kamat Kama and it's a pleasure to welcome, once again, to our forum Professor Josh Meeks, who has been with us a few times before talking about different things in bladder cancer.
